Clinical trial
Evaluation of Valproic Acid (VPA) as Adjunctive Therapy for Trauma Patients With Moderate to Severe Hemorrhage at Risk of Ischemia Reperfusion (I/R) Injury
NCT04531579 is registered in ClinicalTrials.gov with Westat as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Valproic Acid (VPA) as Adjunctive Therapy for Trauma Patients With Moderate to Severe Hemorrhage at Risk of Ischemia Reperfusion (I/R) Injury
- Lead sponsor
- Westat
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- January 31, 2022
- Completion date
- June 30, 2023
- Enrollment
- 0 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
acute kidney injury, ischemia reperfusion injury